Cost-effectiveness of nivolumab combined with chemotherapy as a first-line therapy for patients with unresectable or metastatic urothelial carcinoma

Background: Urothelial carcinoma is a significant health concern in the United States (US), with high mortality and economic burdens. The CheckMate-901 trial showed promising survival benefits for nivolumab combined with gemcitabine and cisplatin followed by nivolumab maintenance therapy (nivolumab-...

詳細記述

書誌詳細

出版年:	Therapeutic Advances in Medical Oncology
主要な著者:	Jingwen Lin, Xiaobing Song, Wu Fu, Caicong You, Na Li, Maobai Liu, Hongfu Cai
フォーマット:	論文
言語:	英語
出版事項:	SAGE Publishing 2024-12-01
オンライン･アクセス:	https://doi.org/10.1177/17588359241301339